BBLN:NYE-Babylon Holdings Ltd (USD)

COMMON STOCK | Health Information Services | NYE

Last Closing Price

USD 6.52

Change

0.00 (0.00)%

Market Cap

USD 2.67B

Volume

0.25M

Avg Analyst Target

USD 11.75 (+80.21%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Babylon Holdings Ltd (BBLN) Stock Analysis:
Based on the Babylon Holdings Ltd stock forecasts from 4 analysts, the average analyst target price for Babylon Holdings Ltd is USD 11.75 over the next 12 months. Babylon Holdings Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Babylon Holdings Ltd is Very Bearish, which is based on 0 positive signals and 2 negative signals. At the last closing, Babylon Holdings Ltd’s stock price was USD 6.52. Babylon Holdings Ltd’s stock price has changed by +0.77% over the past week, +0.17% over the past month and +0.00% over the last year.

About

Babylon Holdings Limited operates as a digital healthcare company. The company provides assistance to navigate the health system by connecting patients digitally to the clinicians. It operates in the United Kingdom, the United States, the Asia Pacific, Canada, and internationally ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VEEV Veeva Systems Inc

N/A

USD34.42B 84.15 75.37
TDOC Teladoc Health Inc

N/A

USD12.74B N/A N/A
DOCS Doximity Inc.

N/A

USD8.63B 96.91 98.73
AGTI Agiliti Inc

N/A

USD2.62B 200.80 13.13
EVH Evolent Health Inc

N/A

USD2.27B N/A 64.61
PHR Phreesia Inc

N/A

USD1.82B 2.91 N/A
AMWL American Well Corporation

N/A

USD1.21B N/A N/A
CNVY Convey Holding Parent Inc.

N/A

USD0.56B N/A 14.37
CSLT Castlight Health Inc

N/A

USD0.33B N/A N/A
NXU Novus Capital Corporation II

N/A

N/A N/A N/A

ETFs Containing BBLN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.84% 91% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.84% 91% A- 94% A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.67B 70% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1,194.23 10% F 0% N/A
Price / Cash Flow Ratio -18.63 70% C- 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -169.28% 20% F 6% F
Return on Invested Capital -122.66% 10% F 1% F
Return on Assets -40.05% 11% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.27 80% B- 44% F
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.